Official Title
Ciclesonide Clinical Trial for COVID-19 Treatment
Brief Summary

The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used and is readily available. It has a low rate of side effects and few interactions with other drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect. Investigators propose to use inhaled and nasal ciclesonide to stop viral replication in the nose and airways. Investigators hope this will accelerate recovery from COVID-19 illness in individuals who are not admitted to hospital at time of diagnosis of COVID-19.

Terminated
COVID 19

Drug: Normal Saline intranasal and placebo inhaler

Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID

Drug: Ciclesonide

Ciclesonide 600mcg BID inhaled with aero chamber
Other Name: Alvesco

Drug: Ciclesonide nasal

intranasal ciclesonide 200 mcg DIE
Other Name: Omnaris

Eligibility Criteria

Inclusion Criteria:

Symptomatic adult patients positive by PCR for COVID-19 within 5 days of enrollment with
fever, cough, or shortness of breath. Provision of Informed Consent

At day 0, patients should be at home

Exclusion Criteria:

- Already on inhaled corticosteroid medication

- Currently using systemic steroids (oral or intravenous or intramuscular such as
Prednisone) or use of steroids 7 days prior to enrolment

- Severely ill patients at enrollment (i.e., admitted to ICU at admission)

- Unable to self-administer the inhaler

- Known or suspected pregnancy and breastfeeding

- Known allergy to study medication or its components (non-medicinal ingredients;
including lactose allergy (type I))

- Patients with untreated fungal, bacterial, or tubercular infections of the respiratory
tract

- Current hospitalization

- Current use of oxygen at home or in the hospital

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Canada
Locations

University of British Columbia
Vancouver, British Columbia, Canada

Sunnybrook Hospital
Toronto, Ontario, Canada

McGill University Health Center
Montreal, Quebec, Canada

McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT Number
MeSH Terms
COVID-19
Ciclesonide